Lantern Pharma Inc. (LTRN)

Lantern Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6.66	4.42	7.51	21.94	37.2	51.52
Short-Term Investments	0.7	5.7	16.5	19.36	17.99	19.2
Cash & Short-Term Investments	7.36	10.12	24.01	41.3	55.2	70.73
Cash Growth	-53.71%	-57.86%	-41.86%	-25.17%	-21.96%	267.80%
Other Receivables	0.03	0.03	0.1	0.86	0.59	0.18
Receivables	0.03	0.03	0.1	0.86	0.59	0.18
Prepaid Expenses	0.58	0.65	1.14	1.18	0.76	1.03
Restricted Cash	-	-	-	-	0.54	-
Other Current Assets	0.48	-	-	-	1.63	0.78
Total Current Assets	8.46	10.8	25.25	43.34	58.72	72.72
Property, Plant & Equipment	0.06	0.11	0.29	0.28	0.1	0.22
Long-Term Deferred Charges	0.05	0.09	-	-	-	-
Other Long-Term Assets	0.03	0.04	0.04	0.03	0.02	1.02
Total Assets	8.6	11.04	25.57	43.65	58.84	73.95

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.35	3.06	2.42	0.94	0.93	0.68
Current Portion of Leases	0.04	0.08	0.19	0.17	0.05	0.15
Other Current Liabilities	0.94	1.36	1.73	1.56	1.81	1.49
Total Current Liabilities	4.32	4.5	4.33	2.68	2.8	2.33
Long-Term Leases	-	-	0.05	0.06	-	0.05
Total Liabilities	11.82	4.5	4.38	2.74	2.8	2.38

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	100.37	99.65	97.06	96.26	95.69	96.69
Retained Earnings	-103.55	-93.15	-76.03	-55.24	-39.28	-25.02
Comprehensive Income & Other	-0.04	0.03	0.15	-0.11	-0.37	-0.09
Total Common Equity	-3.22	6.53	21.19	40.91	56.04	71.57
Shareholders' Equity	-3.22	6.53	21.19	40.91	56.04	71.57
Total Liabilities & Equity	8.6	11.04	25.57	43.65	58.84	73.95

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.04	0.08	0.24	0.23	0.05	0.2
Net Cash (Debt)	7.32	10.04	23.77	41.07	55.14	70.52
Net Cash Growth	-53.53%	-57.76%	-42.12%	-25.52%	-21.80%	268.82%
Net Cash Per Share	0.64	0.92	2.21	3.79	5.08	6.47
Filing Date Shares Outstanding	12.78	11.25	10.78	10.74	10.86	10.78
Total Common Shares Outstanding	12.76	11.25	10.78	10.72	10.86	11.09
Working Capital	4.14	6.3	20.92	40.66	55.92	70.39
Book Value Per Share	-0.25	0.58	1.96	3.82	5.16	6.45
Tangible Book Value	-3.22	6.53	21.19	40.91	56.04	71.57
Tangible Book Value Per Share	-0.25	0.58	1.96	3.82	5.16	6.45

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 15, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 30, 2026

Data Sources Report a data error